GoAI
Get started
Shattuck Labs, Inc. logo

Shattuck Labs, Inc.

STTK

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$7.53

+$0.28 · +3.86%

Aug 21, 4:00 PM ET

STTK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

11

Overpriced

Momentum

76

Gaining

Sentiment

73

Bullish

Risk resilience

46

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Taylor H. Schreiber
Listed since
Oct 9, 2020
Employees
40

Market position

Day range

Current $7.53

52-week range

Current $7.53

Open
$7.36
Previous close
$7.25
Volume
475.59K
0.44× average
Average volume
1.08M
Average daily volume
Market cap
680.5M USD
Beta
1.11
Market reference 1
50-day average
$6.6908
+12.54% above average
200-day average
$5.2181
+44.31% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
202.21M USD
P/E (TTM)
-14.76×
P/B (TTM)
4.63×
P/S (TTM)
680.5×
EV / EBITDA
-4.48×
Earnings yield
-19.22%
Free cash flow yield
-15.73%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-750.90%
Operating margin
-5578.70%
Net margin
-5256.80%
Return on equity
-59.24%
Return on assets
-53.62%
Return on invested capital
-60.73%

Financial health

Debt / equity
0.01×
Current ratio
11.7×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends1690%-4688%-11065%-17442%Gross margin, FY2021: 95.40%Gross margin, FY2022: -12507.21%Gross margin, FY2023: -143.93%Gross margin, FY2024: 14.46%Gross margin, FY2025: -195.10%Operating margin, FY2021: -150.81%Operating margin, FY2022: -15848.01%Operating margin, FY2023: -5549.61%Operating margin, FY2024: -1408.27%Operating margin, FY2025: -5150.80%Net margin, FY2021: -149.83%Net margin, FY2022: -15635.74%Net margin, FY2023: -5268.44%Net margin, FY2024: -1318.13%Net margin, FY2025: -4880.90%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 95.40%. Gross margin FY2022 -12507.21%. Gross margin FY2023 -143.93%. Gross margin FY2024 14.46%. Gross margin FY2025 -195.10%. Operating margin FY2021 -150.81%. Operating margin FY2022 -15848.01%. Operating margin FY2023 -5549.61%. Operating margin FY2024 -1408.27%. Operating margin FY2025 -5150.80%. Net margin FY2021 -149.83%. Net margin FY2022 -15635.74%. Net margin FY2023 -5268.44%. Net margin FY2024 -1318.13%. Net margin FY2025 -4880.90%.

Income trends

Revenue

1M USD-82.52%

Operating income

−51.51M USD+36.07%

Net income

−48.81M USD+35.28%
Income trends across reported periods43.35M USD−9.99M USD−63.33M USD−116.66M USDRevenue, FY2021: 30.02M USDRevenue, FY2022: 652K USDRevenue, FY2023: 1.66M USDRevenue, FY2024: 5.72M USDRevenue, FY2025: 1M USDOperating income, FY2021: −45.27M USDOperating income, FY2022: −103.33M USDOperating income, FY2023: −91.96M USDOperating income, FY2024: −80.57M USDOperating income, FY2025: −51.51M USDNet income, FY2021: −44.97M USDNet income, FY2022: −101.95M USDNet income, FY2023: −87.3M USDNet income, FY2024: −75.41M USDNet income, FY2025: −48.81M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 30.02M USD. Revenue FY2022 652K USD. Revenue FY2023 1.66M USD. Revenue FY2024 5.72M USD. Revenue FY2025 1M USD. Operating income FY2021 −45.27M USD. Operating income FY2022 −103.33M USD. Operating income FY2023 −91.96M USD. Operating income FY2024 −80.57M USD. Operating income FY2025 −51.51M USD. Net income FY2021 −44.97M USD. Net income FY2022 −101.95M USD. Net income FY2023 −87.3M USD. Net income FY2024 −75.41M USD. Net income FY2025 −48.81M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1M USD5.72M USD1.66M USD652K USD30.02M USD
Cost of goods sold2.95M USD4.89M USD4.04M USD82.2M USD1.38M USD
Gross profit−1.95M USD827K USD−2.39M USD−81.55M USD28.64M USD
Research and development35.27M USD67.21M USD74.31M USD82.9M USD56.56M USD
Selling, general, and administrative17.24M USD19.08M USD19.3M USD19.68M USD18.72M USD
Operating expenses49.56M USD81.39M USD89.57M USD21.78M USD73.91M USD
Interest income2.7M USD5.17M USD4.67M USD1.59M USD625K USD
Depreciation and amortization3.69M USD3.83M USD4.04M USD3.07M USD1.38M USD
Operating income−51.51M USD−80.57M USD−91.96M USD−103.33M USD−45.27M USD
Net income−48.81M USD−75.41M USD−87.3M USD−101.95M USD−44.97M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 1 miss, 1 met estimate
Average EPS surprise
+8.05%
11 comparable reports
Latest EPS result
-0.12
Estimate -0.12 · Beat by 3.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.2-0.31-0.42Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MetQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 27, 2025: actual -0.37, estimate -0.38, surprise +2.63%, Beat. Q2 2025, reported May 1, 2025: actual -0.27, estimate -0.29, surprise +6.90%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.24, estimate -0.25, surprise +4.00%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.14, estimate -0.15, surprise +6.67%, Beat. Q1 2026, reported Mar 5, 2026: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q2 2026, reported May 7, 2026: actual -0.13, estimate -0.14, surprise +7.14%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.12, estimate -0.124, surprise +3.28%, Beat. Q4 2026, reported Nov 10, 2026: actual —, estimate -0.1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates15.64M10.47M5.31M141.67KQ1 '24BeatQ2 '24BeatQ3 '24BeatQ4 '24BeatQ1 '25BeatQ4 '25BeatQ1 '26Estimate
Q1 2024, reported Feb 29, 2024: actual 714K USD, estimate 200K USD, surprise +257.00%, Beat. Q2 2024, reported May 2, 2024: actual 1.12M USD, estimate 304.67K USD, surprise +265.97%, Beat. Q3 2024, reported Aug 1, 2024: actual 1.61M USD, estimate 580K USD, surprise +177.41%, Beat. Q4 2024, reported Nov 14, 2024: actual 3M USD, estimate 250K USD, surprise +1098.80%, Beat. Q1 2025, reported Mar 27, 2025: actual 14.49M USD, estimate 799.4K USD, surprise +1712.86%, Beat. Q4 2025, reported Nov 6, 2025: actual 1M USD, estimate 166.67K USD, surprise +499.99%, Beat. Q1 2026, reported Mar 5, 2026: actual —, estimate 250K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.00

59.36% upside
Past 12 months12-month forecastHigh $16.00Average $12.00Low $7.00

Rating distribution

9 ratings
Strong buy00%
Buy9100%
Hold00%
Sell00%
Strong sell00%

STTK peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding STTK

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
16.73M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
11.24M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
5.44M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
3.64M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
2.68M
Weight
0.04%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
2.43M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.53M
Weight
0.10%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
1.09M
Weight
0.01%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%

Continue in GoAI

Research STTK

research.disclaimer